S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
NASDAQ:FGEN

FibroGen - FGEN Stock Forecast, Price & News

$24.85
+0.46 (+1.89%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$24.10
$24.93
50-Day Range
$13.85
$24.85
52-Week Range
$7.81
$24.93
Volume
945,442 shs
Average Volume
1.10 million shs
Market Capitalization
$2.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

FibroGen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
15.5% Downside
$21.00 Price Target
Short Interest
Healthy
6.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.42mentions of FibroGen in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$137,810 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.38) to ($2.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

781st out of 1,030 stocks

Pharmaceutical Preparations Industry

390th out of 502 stocks

FGEN stock logo

About FibroGen (NASDAQ:FGEN) Stock

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FGEN Stock News Headlines

FibroGen (NASDAQ:FGEN) Stock Price Up 4.5%
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
FibroGen (NASDAQ:FGEN) Upgraded by William Blair to "Outperform"
FibroGen (NASDAQ:FGEN) Upgraded to Outperform at Raymond James
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
FibroGen Third Quarter 2022 Earnings: Misses Expectations
FibroGen (FGEN) Reports Q3 Loss, Misses Revenue Estimates
FibroGen to Report Third Quarter 2022 Financial Results
FibroGen - Biotech - Seeking Alpha
FibroGen Reaches Analyst Target Price - Nasdaq
See More Headlines
Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FGEN Company Calendar

Last Earnings
11/07/2022
Today
2/02/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FGEN
Employees
566
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
-15.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-290,020,000.00
Net Margins
-294.16%
Pretax Margin
-295.20%

Debt

Sales & Book Value

Annual Sales
$235.31 million
Book Value
$2.47 per share

Miscellaneous

Free Float
91,308,000
Market Cap
$2.33 billion
Optionable
Optionable
Beta
0.85

Key Executives

  • Enrique A. Conterno
    Chief Executive Officer & Director
  • Juan Graham
    Chief Financial Officer & Senior Vice President
  • Michael Martinelli
    Senior Vice President-Technical Development
  • Elias Kouchakji
    Senior VP-Clinical Development & Drug Safety
  • Mark Eisner
    Chief Medical Officer













FGEN Stock - Frequently Asked Questions

Should I buy or sell FibroGen stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FGEN shares.
View FGEN analyst ratings
or view top-rated stocks.

What is FibroGen's stock price forecast for 2023?

4 equities research analysts have issued 12 month target prices for FibroGen's stock. Their FGEN share price forecasts range from $8.00 to $35.00. On average, they anticipate the company's stock price to reach $21.00 in the next year. This suggests that the stock has a possible downside of 15.3%.
View analysts price targets for FGEN
or view top-rated stocks among Wall Street analysts.

How have FGEN shares performed in 2023?

FibroGen's stock was trading at $16.02 at the beginning of 2023. Since then, FGEN shares have increased by 54.7% and is now trading at $24.78.
View the best growth stocks for 2023 here
.

Are investors shorting FibroGen?

FibroGen saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 5,820,000 shares, a decline of 13.3% from the December 31st total of 6,710,000 shares. Based on an average daily trading volume, of 890,500 shares, the days-to-cover ratio is currently 6.5 days. Currently, 6.7% of the company's stock are short sold.
View FibroGen's Short Interest
.

When is FibroGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our FGEN earnings forecast
.

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) released its quarterly earnings data on Monday, November, 7th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by $0.15. The biopharmaceutical company earned $15.74 million during the quarter, compared to analyst estimates of $34.02 million. FibroGen had a negative net margin of 294.16% and a negative trailing twelve-month return on equity of 250.58%.

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by many different institutional and retail investors. Top institutional shareholders include State of New Jersey Common Pension Fund D (0.18%), Pinnacle Associates Ltd. (0.17%), Pinnacle Associates Ltd. (0.16%), Zurcher Kantonalbank Zurich Cantonalbank (0.10%), New York State Common Retirement Fund (0.10%) and Strs Ohio (0.05%). Insiders that own company stock include Christine Chung, Enrique A Conterno, Juan Graham, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr.
View institutional ownership trends
.

How do I buy shares of FibroGen?

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $24.78.

How much money does FibroGen make?

FibroGen (NASDAQ:FGEN) has a market capitalization of $2.33 billion and generates $235.31 million in revenue each year. The biopharmaceutical company earns $-290,020,000.00 in net income (profit) each year or ($3.89) on an earnings per share basis.

How many employees does FibroGen have?

The company employs 566 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902.

This page (NASDAQ:FGEN) was last updated on 2/3/2023 by MarketBeat.com Staff